Planned system outage: A number of IT systems will be temporarily unavailable on 7 March 2026 from 10am–6pm AEDT due to scheduled maintenance. 

Full details

Planned library system outage: Access to library e-resources - including all e-books and e-journals - will be impacted by a system upgrade on Wednesday, 18 February 2026 from 8AM - 12PM AEDT / 10AM - 2PM NZDT.

Further information

The college will be closed from 2pm (AEDT) on Wednesday 24 December 2025 until Monday 5 January 2026. We wish you a happy and safe festive period.

MyPortfolio is now available via https://myportfolio.anzca.edu.au/. Please contact the ANZCA Training team at [email protected] if you have any queries or require assistance.

Anaesthesia reversal agents: investigating a presynaptic target mechanism

Project Grant

The study sought to address whether a fluorinated analogue of propofol could work as a reversal agent for propofol under experimental conditions in cell culture and an animal model. Two different readouts were examined in cell culture: neurotransmitter release and protein dynamics. Propofol impairs both by decreasing neurotransmission and immobilising key presynaptic proteins such as munc-18 and syntaxin1A, which are important for normal neurotransmission. The researchers first sought to confirm these effects in a new cell culture preparation and then determine whether these effects could be reversed by adding propofluor to the anaesthetic solution.

A second part of the project examined where propofol might bind to key presynaptic proteins such as syntaxin1A and munc-18, and whether adding propofluor might displace propofol from these sites. This approach would provide a tentative explanation for any reversal effects observed in the first aim.

Royal Brisbane and Women’s Hospital, Queensland
Professor Andre van Zundert
Professor Victoria Eley

Queensland Brain Institute
Professor Bruno van Swinderen

The project was awarded A$70,000 funding through the ANZCA research grants program for 2024.   

The study sought to address whether a fluorinated analogue of propofol could work as a reversal agent for propofol, under experimental conditions in cell culture and an animal model. The researchers examined two different readouts in cell culture: neurotransmitter release, and protein dynamics. Propofol impairs both, by decreasing neurotransmission and immobilising key presynaptic proteins such as munc-18 and syntaxin1A, which are important proteins for making neurotransmission work normally. They study sought to confirm these effects in a new cell culture preparation, and find if these effects could be overturned by adding propofluor to the anaesthetic solution.

A second part of the project asked where propofol might be binding to key presynaptic proteins such as syntaxin1A and munc-18, and whether adding propofluor might be displacing propofol from these sites. This approach would provide a tentative explanation for any reversal effects would be observed in the first aim.

The finding that propofluor reliably overturns the effect of propofol on neurotransmission, across different systems, now provides a powerful readout for dissecting the molecular underpinnings of this phenomenon. Clearly, whatever is being overturned by propofluor should be represented at another level of investigation, such as single molecule imaging or photoaffinity labelling. The outcomes of this project should therefore begin to address the question of how propofluor is working, and in consequence, how propofol is achieving its effect on presynaptic neurotransmission.

Finding that propofluor overturned the effects of propofol on neurotransmission was expected, as the researchers already had preliminary data of the same from neuronal cultures. This confirmation is highly encouraging as it shows using two completely different assays that this presynaptic endpoint of propofol can effectively be overturned and thus presents propofluor as a viable candidate for further experiments in mammalian models and eventual clinical trials.

It was surprising to find that whilst propofluor rescued neurotransmission, it did not seem to rescue munc-18 mobility in the same stimulated cell preparation. This suggests that munc-18 might not be relevant to the mechanism whereby propofluor counteracts the effects of propofol. It will be interesting to see in this regard whether propofluor overturns the effects of propofol on syntaxin1A mobility (also part of the project plan). If it does, then that would argue that the drug effects are working through syntaxin1A and not munc-18, thereby narrowing our search for the target mechanism. The outcome of this strategy should also be consistent with the results from out photoaffinity labelling experiments. These finding will increase our basic scientific knowledge on how drugs like propofol actually work, and whether a reversal agent such as propofluor can proceed to clinical trials.

It was also important in this regard to confirm that propofluor is not toxic, i.e., that it does not kill animals such as C. elegans nematodes. While propofluor seemed to somewhat impair worm crawling speed, the animals remained healthy and fully recovered from exposure to propofluor, as they do for propofol as well (data not shown). This further established our nematode assay as a valuable complement to our cell culture assays in determining the viability of potential anaesthesia reversal agents.

Investigating Reversal Mechanisms of General Anaesthesia. 2024 Drew Min Su Cylinder, Adam Hines, Amber Kewin, Jenny Dunn, André Van Zundert, Bruno van Swinderen. Australasian Neuroscience Society Conference.

Last modified: